Starton Therapeutics (STA)
Market Price (12/4/2025): $283.55 | Market Cap: $8.6 BilSector: Health Care | Industry: Biotechnology
Starton Therapeutics (STA)
Market Price (12/4/2025): $283.55Market Cap: $8.6 BilSector: Health CareIndustry: Biotechnology
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -11 Mil |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -11 Mil |
Valuation, Metrics & Events
STA Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
Here are key points explaining why Starton Therapeutics (STA) stock may have moved by 0% for the approximate time period from August 31, 2025, to December 4, 2025:
1. No major clinical trial results or regulatory approvals announced. Despite being a clinical-stage biotechnology company with ongoing clinical development, there were no announcements of significant new clinical trial data, regulatory submissions, or approvals during this period that would typically act as strong catalysts for stock price movement. While positive Phase 1b data for STAR-LLD was presented in April 2025 and a Phase 2a clinical trial was open for enrollment in June 2025, there were no updates on these critical milestones between August and December 2025.
2. Patent grant not perceived as an immediate value driver. Starton Therapeutics was granted a new U.S. Patent (#12,390,457) on September 16, 2025, for its stable solutions of immunomodulatory imide compounds, a formulation of STAR-LLD. While patent grants are generally positive, the market might have already factored in the potential for such intellectual property, or viewed its commercial impact as longer-term, thus not leading to an immediate stock price appreciation.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| STA Return | 5% | 14% | 22% | 4% | 29% | 0% | 97% |
| Peers Return | 6% | -1% | -7% | -13% | -25% | 2% | -34% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| STA Win Rate | 67% | 58% | 58% | 58% | 75% | 0% | |
| Peers Win Rate | 29% | 21% | 25% | 27% | 15% | 40% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| STA Max Drawdown | -40% | -4% | -2% | -14% | 0% | 0% | |
| Peers Max Drawdown | -19% | -10% | -17% | -24% | -25% | -2% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, ACSB, AIXC, ALPS, APRI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)
How Low Can It Go
| Event | STA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -19.8% | -25.4% |
| % Gain to Breakeven | 24.7% | 34.1% |
| Time to Breakeven | 58 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -42.2% | -33.9% |
| % Gain to Breakeven | 73.0% | 51.3% |
| Time to Breakeven | 301 days | 148 days |
| 2018 Correction | ||
| % Loss | -24.9% | -19.8% |
| % Gain to Breakeven | 33.2% | 24.7% |
| Time to Breakeven | 172 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -46.3% | -56.8% |
| % Gain to Breakeven | 86.1% | 131.3% |
| Time to Breakeven | 755 days | 1480 days |
Compare to VRTX, ACSB, AIXC, ALPS, APRI
In The Past
Starton Therapeutics's stock fell -19.8% during the 2022 Inflation Shock from a high on 3/25/2022. A -19.8% loss requires a 24.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Trade Ideas
Select past ideas related to STA. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 10.0% | 10.0% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.7% | -7.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.9% | 6.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 11.5% | 11.5% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 8.9% | 8.9% | -5.1% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 10.0% | 10.0% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.7% | -7.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.9% | 6.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 11.5% | 11.5% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 8.9% | 8.9% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Starton Therapeutics
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 2.54 |
| Mkt Cap | 118.4 |
| Rev LTM | 0 |
| Op Inc LTM | -11 |
| FCF LTM | 1,665 |
| FCF 3Y Avg | 1,027 |
| CFO LTM | 1,856 |
| CFO 3Y Avg | 1,204 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.3% |
| Rev Chg 3Y Avg | 10.5% |
| Rev Chg Q | 11.0% |
| QoQ Delta Rev Chg LTM | 2.7% |
| Op Mgn LTM | -0.8% |
| Op Mgn 3Y Avg | 26.2% |
| QoQ Delta Op Mgn LTM | 1.0% |
| CFO/Rev LTM | 31.7% |
| CFO/Rev 3Y Avg | 23.1% |
| FCF/Rev LTM | 28.5% |
| FCF/Rev 3Y Avg | 19.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 118.4 |
| P/S | 8.5 |
| P/EBIT | 22.4 |
| P/E | 27.2 |
| P/CFO | 26.9 |
| Total Yield | 3.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.3% |
| D/E | 0.0 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 8.7% |
| 3M Rtn | 16.8% |
| 6M Rtn | 3.9% |
| 12M Rtn | 1.3% |
| 3Y Rtn | 44.1% |
| 1M Excs Rtn | 8.7% |
| 3M Excs Rtn | 11.3% |
| 6M Excs Rtn | -10.8% |
| 12M Excs Rtn | -14.6% |
| 3Y Excs Rtn | -25.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 6302023 | 9212023 | S-4/A 6/30/2023 |
| 3312023 | 7132023 | S-4/A 3/31/2023 |
| 3312022 | 5152023 | S-4 3/31/2022 |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |